News | August 07, 2024
Gland Pharma posts 16% revenue growth in Q1 FY25
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated
